Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. H.J. (Hiddo) Lambers Heerspink

Publicaties

Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial

Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence

Authors’ Reply: Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?

Canagliflozin and iron metabolism in the CREDENCE trial

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials

Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

Compositions and methods for treating and preventing kidney disease

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy”

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease: A practical update for clinicians

Pers/media

Hoe afslankmedicijnen het hele lichaam veranderen: ‘Mijn hoofd roept niet meer om eten’

智康弘义宣布SC0062临床II期糖尿病肾病队列研究达到12周主要终点 | 项目进展

Diabetesmedicijn Ozempic heeft ook positief effect bij chronische nierschade

Semaglutide in patinenten met nierziekte

BioCity announces its endothelin receptor A selective antagonist SC0062 met the ...

Zibotentan, Dapagliflozin Combo Further Reduces Albuminuria in CKD

New Hope for Treating Chronic Kidney Disease in Type 1 Diabetes